Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course versus long-course methylprednisolone maintenance for newly diagnosed primary immune thrombocytopenia
ChiCTR-IIR-16008994Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone in immune thrombocytopenia (ITP) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Weekly proportion achieving platelet response, Weekly proportion achieving complete platelet response and 3 more. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR-IIR-16008994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008994.